Maxx Medical, Pvt. Ltd., the parent company of Maxx Orthopedics, Inc., is pleased to announce that the Freedom Total Knee® System has received Drugs Controller General of India (DCGI) approval following US FDA approval received earlier this year. The Freedom Knee is expected to be available in the Indian market by early September 2009.
"With more than 165 million people currently over age 65, India is a primary market for us," said Ashesh Shah, CEO, Maxx Medical. "The economic emergence of this region has been a driver of innovation for us and we’re committed to providing outstanding joint replacement products and in-region customer service to support India’s increasing orthopedic-related needs."
Leading orthopedic and biomedical design experts collaborated to develop the Freedom Knee, building on advanced engineering technologies and deep clinical expertise to enhance every aspect of the total knee arthroplasty surgical experience, from instruments to implants. The Freedom Knee features the only known all-poly tibial liner approved for high flexion by the US FDA. Additionally, the system design preserves bone, while accommodating the high-flexion motion needed to comfortably perform daily activities.
"DCGI approval enables us to bring the Freedom Knee’s advanced orthopedic design concept and philosophy to the Indian market, where high-flexion motion needed for deep knee bending is especially relevant," said Tarak Buch, Head of Asia Operations for Maxx Medical.
For more information about the Freedom Knee, including sales and distribution opportunities or clinical trial participation, interested parties can visit www.maxxmed.com or email email@example.com.